Wall Street brokerages predict that Solid Biosciences Inc (NASDAQ:SLDB) will announce ($0.62) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Solid Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.66) and the highest estimate coming in at ($0.58). Solid Biosciences posted earnings per share of ($0.55) during the same quarter last year, which suggests a negative year-over-year growth rate of 12.7%. The company is scheduled to report its next quarterly earnings report on Tuesday, November 12th.

On average, analysts expect that Solid Biosciences will report full year earnings of ($2.85) per share for the current financial year, with EPS estimates ranging from ($3.05) to ($2.68). For the next year, analysts expect that the business will report earnings of ($2.06) per share, with EPS estimates ranging from ($2.17) to ($1.91). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that cover Solid Biosciences.

Solid Biosciences (NASDAQ:SLDB) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.05.

Several analysts have recently commented on the stock. Goldman Sachs Group downgraded shares of Solid Biosciences from a “neutral” rating to a “sell” rating and lowered their target price for the company from $5.00 to $4.00 in a report on Tuesday, May 14th. Credit Suisse Group cut Solid Biosciences from a “neutral” rating to an “underperform” rating and decreased their price target for the company from $7.00 to $6.00 in a research report on Tuesday, May 14th. Leerink Swann raised shares of Solid Biosciences from a “market perform” rating to an “outperform” rating in a report on Monday, August 19th. Citigroup lowered shares of Solid Biosciences from a “neutral” rating to a “sell” rating and set a $6.00 price target for the company. in a research report on Thursday, August 29th. Finally, ValuEngine raised shares of Solid Biosciences from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Three analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. Solid Biosciences currently has an average rating of “Hold” and an average target price of $8.67.

In other Solid Biosciences news, Director Life Sciences Maste Perceptive bought 2,822,581 shares of the firm’s stock in a transaction on Thursday, July 25th. The stock was acquired at an average price of $4.65 per share, with a total value of $13,125,001.65. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 31.20% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SLDB. BlackRock Inc. raised its position in Solid Biosciences by 10.9% in the second quarter. BlackRock Inc. now owns 1,328,852 shares of the company’s stock worth $7,640,000 after acquiring an additional 130,516 shares during the period. Vanguard Group Inc. boosted its holdings in Solid Biosciences by 11.7% in the second quarter. Vanguard Group Inc. now owns 830,325 shares of the company’s stock worth $4,774,000 after acquiring an additional 87,016 shares in the last quarter. EcoR1 Capital LLC acquired a new stake in Solid Biosciences in the second quarter worth about $4,755,000. Spark Investment Management LLC boosted its holdings in Solid Biosciences by 78.7% in the first quarter. Spark Investment Management LLC now owns 318,100 shares of the company’s stock worth $2,926,000 after acquiring an additional 140,141 shares in the last quarter. Finally, Emory University grew its stake in shares of Solid Biosciences by 335.0% during the first quarter. Emory University now owns 298,887 shares of the company’s stock worth $2,750,000 after acquiring an additional 230,173 shares during the last quarter. 46.29% of the stock is currently owned by hedge funds and other institutional investors.

Shares of SLDB stock traded up $0.08 during trading on Friday, hitting $10.60. The company had a trading volume of 570,148 shares, compared to its average volume of 695,131. The stock’s 50-day moving average price is $7.38 and its 200 day moving average price is $7.60. Solid Biosciences has a one year low of $4.32 and a one year high of $54.54. The firm has a market capitalization of $454.01 million, a P/E ratio of -4.71 and a beta of 1.82. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.73 and a current ratio of 5.73.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles.

Further Reading: What is net income?

Get a free copy of the Zacks research report on Solid Biosciences (SLDB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Solid Biosciences (NASDAQ:SLDB)

Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.